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Summary The normal growth, development and function of an organism requires precise and co-ordinated
control of gene expression. A major part of this control is exerted by regulating messenger RNA (mRNA)
production and involves complex interactions between an array oftranscriptionally active proteins and specific
regulatory DNA sequences. The combination of such proteins and DNA sequences is specific for given gene or
group of genes in a particular cell type and the proteins regulating the same gene may vary between cell types.
In addition the expression or activity of these regulatory proteins may be modified depending on the state of
differentiation of a cell or in response to an external stimulus. Thus, the differentiation ofembryonic cells into
diverse tissues is achieved and the mature structure and function of the organism is maintained. This review
focusses on the role of perturbations of these transcriptional controls in neoplasia. Deregulation of transcrip-
tion may result in the failure to express genes responsible for cellular differentation, or alternatively, in the
transcription of genes involved in cell division, through the inappropriate expression or activation ofpositively
acting transcription factors and nuclear oncogenes. Whether the biochemical abnormalities that lead to the
disordered growth and differentiation of a malignant tumour affect cell surface receptors, membrane or
cytoplasmic signalling proteins or nuclear transcription factors, the end result is the inappropriate expression
of some genes and failure to express others. Current research is starting to elucidate which of the elements of
this complicated system are important in neoplasia.
The appearance and behaviour of cancer cells is a conse-
quence of failure of normal regulation of expression of genes
involved in cell growth and differentiation. There is inappro-
priate production of growth factors or growth factor recep-
tors (Roberts & Sporn, 1985), the expression or loss of
surface antigens, such as HLA molecules (Bernards, 1987), of
structural proteins and of enzymes and excessive and unco-
ordinated cell replication. Since all somatic cells have the
same complement of DNA, mechanisms are necessary to
allow differential expression of proteins by the various cell
types and also by the same cell type at different times, for
example, in response to external stimuli or during the process
of growth and development.
Transcription is the process of copying a part of the DNA
template carrying the genetic code into messenger RNA
(mRNA). This is then modified and travels to the cytoplasm,
where it is translated into the amino acid sequence of the
encoded protein. Regulation of transcription is of fundamen-
tal importance in the control of gene expression during such
diverse events as the development of body segments by flies
(Akam, 1987; Scott & Carroll, 1987), neurogenesis in worms
(Finney et al., 1988) and for muscle differentiation (Davies et
al., 1990), B-lymphocyte-specific immunoglobulin production
(Lenardo et al., 1987) and the response to steroid hormones
in mammals (Beato, 1989; Evans, 1988). Evidence is now
accumulating that transcriptional deregulation is equally
important in the process of neoplasia.
How transcription is regulated
Tissue specific gene expression
In eukaryotic organisms, mRNA transcription from the
DNA template requires both the general transcriptional
machinery, including RNA polymerase II (pol II) and the
general transcription factors TFIIA-F, and proteins (trans-
acting factors) which specifically recognise short DNA
sequences (cis-acting elements) in the non-coding region of
the gene (Ptashne, 1986; Dynan & Tjian, 1985). These
sequences may be in the DNA immediately preceding (up-
stream of) the transcription start site, where they constitute
the promoter necessary for accurate and efficient initiation of
transcription, but may also lie several thousand bases up-
stream or even within introns or downstream of the gene,
forming enhancers elements, which modulate promoter func-
tion (Maniatis et al., 1987). Since pol II and the general
factors are necessary for the transcription of most, if not all,
active protein coding genes, differential regulation of genes is
determined by the factors interacting with specific cis-acting
elements. Thus, the combination of proteins controlling the
transcription of an individual gene in a particular cell type
depends firstly, upon which cis-acting elements are present in
the promoter and enhancer regions of the gene in question
and secondly, upon which trans-acting factors are expressed
and active within the nucleus (Figure 1). In a simple system,
tissue-specific expression of a set of genes could be achieved
by the production in the tissue of an active transcription
factor capable of interacting with a cis-acting element shared
by those genes. However, the same cis-acting element may be
present in the regulatory region of different genes which are
not coordinately expressed (Johnson & McKnight, 1989) and
in addition several factors capable of recognising the partic-
ular element may be present in the same cell (Dorn et al.,
1987; Chodosh et al., 1988; Raymondjean et al., 1988; Cox et
al., 1988). Regulatory specificity is maintained by varying the
context in which the cis-acting element occurs; the relative
affinity of the factors for the core recognition site (cognate
sequence) may be influenced by flanking DNA sequences,
whilst their activity may be significantly modulated by protein-
protein interactions with other sequence-specific DNA bind-
ing proteins (McKnight & Tjian, 1986). A major refinement
of this relatively simple system has been achieved in eukary-
otic organisms by the evolution of families of transcription
factors which bind to their cognate sequence as homodimers
or as heterodimers (see below) with other family members,
allowing the specific and flexible control of transcription
required for normal cellular function (Smeal et al., 1989;
Benbrook & Jones, 1990; Murre et al., 1989a).
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duction pathways may be activated, resulting in alteration in
the level of transcription of responsive genes (Maniatis et al.,
1987) (Figure 2). This may be achieved via the production of
new transcription factors, e.g. the de novo synthesis of factors
which increase transcription from interferon genes in re-
sponse to viral infection (McDonald et al., 1990; Miyamoto
et al., 1988). Alternatively, the binding or transcriptional
activity of factors already present within the cell may be
modulated. This may be brought about either by covalent
modification, e.g. the activation of cAMP-responsive trans-
cription factors of the cyclic AMP response element binding
protein (CREB) family by protein kinase A-mediated phos-
phorylation (Mellon et al., 1989), or otherwise by the induc-
tion ofconformational change, as occurs when a ligand binds
to one of the steroid hormone receptors (which are transcrip-
tion factors). This results in dissociation from the receptor of
an inhibitory protein and enables it both to bind to its
specific DNA recognition sequence and to activate transcrip-
tion (Beato, 1989; Green & Chambon, 1988).
A further level of regulation is achived by the modulation
of the binding or function of sequence-specific transcription
factors by proteins which do not bind directly to DNA but
which may form part of the transcriptional complex, induc-
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Figure 1 Transcriptional mechanisms ofcell-specific gene expres-
sion. Three cells X, Y and Z differentially express two genes
involved in differentiation (1 and 2) and one gene necessary for
growth (3). Gene 1 is strongly expressed in cell X as a result of
binding of the ubiquitous factor 'a', the homodimer 'b-b', and
factor 'h' to their respective recognition sites. In cell Y, expres-
sion is reduced due to the weaker activity of heterodimer 'b-b2',
whilst in cell Z the absence ofenhancer binding factor 'h' leads to
only a low level of transcription. Gene 2 is expressed moderately
strongly by the combination of factor 'c' or factor 'e' with 'a'.
The production ofenhancer factor 'd' in addition to 'e' leads to a
much greater rate of transcription in cell Y. Gene 3 has a low
level of constitutive transcription in cells Y and Z due to 'a'
acting alone. The activator 'g' in cell Z is unable to function,
whilst in cell X transcription is completely suppressed by factor j,.
Inducible expression
Whilst the above mechanisms enable tissue-specific transcrip-
tion of constitutively expressed genes, many genes are only
activated in response to external stimuli. When a cell
perceives such a stimulus, one of a number of signal trans-
-NM
.J3Gone X
Figure 2 Inducible gene expression. (a). In the resting/unstimu-
lated cell factors 'a', 'b' and 'd' are expressed, however, 'a' and 'b'
are sequestered by specific inhibitory proteins, whilst 'd' is in-
active. (b). Following the binding of ligand (L) to its cell memb-
rane receptor (R), the effector molecule (E) may: (i) modify 'b' or
'Ib' such that 'b' is liberated and can bind to its cognate se-
quence, B; (ii) indirectly stimulate production of a new transcrip-
tion factor 'c' which acts via site C or (iii) covalently modify 'd'
such that it binds to D and is active. It would also be possible for
i, ii and iii to occur upon removal of a stimulus. The binding of
hormone (H) to its intracellular receptor 'a' causes its dissocia-
tion from the inhibitor 'Ia' and facilitates dimerisation and DNA
binding. Any of the above events will result in alteration of the
rate of transcription of the gene 'X'. CM, cytoplasmic membrane,
NM, nuclear membrane.
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ing or repressing transcription. The adenovirus Ela protein
and the Herpes simplex protein, Vmw65, both activate trans-
cription and, whilst the mechanism of transactivation by Ela
is still uncertain, Vmw65 is known to function via direct
interaction with the cellular transcription factor, OCT-l
(O'Hare et al., 1988; O'Hare & Goding, 1988). It is likely
that functional homologues for both viral proteins exist in
normal cells. Alternatively, by forming heterodimers with
related, non-DNA-binding inhibitory proteins, potentially
active factors may be prevented from binding to their cog-
nate sequence (Benezra et al., 1990; Ellis et al., 1990; Garrell
& Modolell, 1990; Baeuerle & Baltimore, 1988). By combin-
ing all of these mechanisms, expression of the vast array of
genes in the eukaryotic genome can be regulated by a much
smaller number of transcription factors.
Differentiation anddevelopment
Besides being necessary for normal cellular function in
mature cells, transcriptional regulation also plays a central
role in the control of differentiation (Figure 3) and thus in
the normal development of an organism. Genetic analysis, in
Drosophila, of mutations leading to major structural abnor-
malities in the embryo or adult, has identified genes whose
products play a pivotal role in development. Many of these
proteins are transcription factors, expressed in closely defined
temporal and spatial domains in the early embryo, which
regulate normal segmentation and anteroposterior positional
development (Akam, 1987; Scott & Carroll, 1987; Gehring,
1987). Proteins with close structural similarity in man and
mouse also show distinct domains of expression and some
appear to define regional boundaries in the early develop-
ment of the central nervous system and mesoderm (Manley &
Levine, 1985; Graham et al., 1989).
Transcriptionfactorfamilies share structuralfeatures
As the genes for various transcriptional factors have been
isolated it has become clear that the proteins they encode can
be grouped together on the basis of shared structural fea-
tures. This homology is particularly marked in the domains
responsible for binding to DNA and for the formation of
homo- or heteromeric complexes. In these regions the amino
acid sequence may show a high degree of conservation
between proteins which are, elsewhere, largely dissimilar.
Relatively minor differences in these areas, for example single
amino acid changes, can change the DNA-binding specificity
of a protein, either directly, or by altering the repertoire of
other proteins with which it can form complexes.
differentiates
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Two structures, the basic-helix-loop-helix (bHLH) and the
leucine zipper, involved in dimer/multimer formation, are
now quite well characterised and show some similar features.
The bHLH motif was originally identified as a region
required for dimerisation and DNA binding in the E12 and
E47 transcription factors that are involved in immuno-
globulin gene expression, in the muscle specific factor, MyoD
and in the myc oncoproteins (Murre et al., 1989a). It has
since been identified in a wide variety of other proteins with
diverse functions ranging from phosphatase gene regulation
in yeast (Ogawa & Oshima, 1990) to neuronal development
in Drosophila (Vilares & Cabrera, 1987). The bHLH motif is
composed of a 13 amino acid region containing several
highly conserved basic amino acids, immediately N-terminal
to two a-helices which are separated by a loop of variable
length (Figure 4a). The helices have hydrophobic amino acids
positioned along one face (hydrophobic amphipathic helix)
(Figure 4d) and it is through these residues that the helices of
one protein molecule are thought to interact with those of
another to form homo- or heteromeric complexes. The
helices do not directly contact the DNA, but the formation
of multimers enables the protein to bind to its cognate
sequence via the adjacent basic region. A second structure,
the leucine zipper, is composed of a single hydrophobic
amphipathic a-helix, with leucines on its hydrophobic face,
through which related proteins can interact (Figure 4c)
(Landschulz et al., 1988a; Kouzarides & Ziff, 1989). As with
the bHLH proteins, this helix may be positioned a specific
distance from a cluster of basic amino acids which mediate
DNA-binding, forming the bZip domain (Vinson et al.,
1989). There is a growing family of bZip transcription factors
several of which are capable of combining as stable and
functionally active homo- and heterodimers (Figure 4b)
(Smeal et al., 1989; Kouzarides & Ziff, 1989; Hai et al.,
1989). A separate group of proteins, which includes the myc
proteins, and transcription factors AP-4 and USF, contain
both a bHLH motif and a leucine zipper (Hu et al., 1990;
Gregor et al., 1990). In these proteins the leucine zipper,
which is required for function, is positioned C-terminal to the
bHLH, and probably cooperates with it in the formation of
homo- and heteromeric complexes.
Two other frequently recurring motifs, the zinc finger and
the homeobox, have been shown to be directly responsible
for sequence specific DNA-binding by families of transcrip-
tion factors. The zinc finger was first described in the trans-
cription factor TFIIIA from the toad Xenopus laevis, where it
occurs nine times (Miller et al., 1985; Brown et al., 1985).
Two pairs of appropriately spaced cysteine or cysteine and
histidine residues form a complex with a zinc ion resulting in
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Figure 3 Differentiation. In the immature pre-Z cell, gene I is inactive due to sequestration offactor 'b' by its inhibitor 'Ib', whilst
the activator 'c' of gene 2 is not expressed. The growth-related gene, 3, is very active due to factors r' and 'g'. When the cell
differentiates, genes I and 2 function due to loss of'Ib' expression, allowing dimerisation of 'b', and production of'e', respectively.
The absence of 'f' and inactivation of 'g' severely reduces transcription of gene 3.654 P.M. COX & C.R. GODING
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Figure 4 Helix-loop-helix and leucine zipper domains. (A) Protein sequence alignment of helix-loop-helix regions of some
eukaryotic transcription factors. Amino acids are represented by the single letter code. Highly conserved residues are boxed.
' denotes amino acid (aa) with hydrophobic side chain; B denotes aa with basic side chain. (B) Protein sequence alignment of
leucine zippers, and basic domains where present, of some eukaryotic transcription factors. Basic domains and conserved leucines
are boxed. (C) Helical wheel representation of helix 2 of human c-myc. The conserved basic residues (open boxes) and lysine
(stippled boxes) all align on one face of the helix. (D) Helical wheel representation of the leucine zipper helix of human c-jun. The
conserved leucines (open boxes) align on the same face of the helix.
the formation of a 'finger' by the intervening amino acids
(Figure 5). The finger structure has been demonstrated by
X-ray crystallography (Diakun et al., 1986) and the require-
ment for zinc shown by the loss of DNA binding in the
presence of ion chelators (Kadonaga et al., 1987). Up to at
least 13 zinc fingers can be present in a single protein, as in
the testis determining factor, involved in sex determination
(Page et al., 1987). In some zinc finger proteins all the fingers
may be identical, but in others they appear to subserve
different functions. For example, Green and Chambon (1987)
have showed that in members of the steroid hormone receptor
family, which all have two fingers, one provides DNA-bind-
ing specificity, whilst the other stabilises the protein-DNA
complex, probably by contacting the phosphate backbone of
the DNA.
The homeobox, was originally identified as a conserved
element in a number of genes involved in segmentation in
Drosophila (Gehring, 1987), but it has since been found in
proteins with various functions from many phyla. Predictions
of the structure of the homeobox based on its amino acid
sequence suggested it would form three stretches of a-helix
separated by short flexible spacers (Laughon & Scott, 1984;
Shepard et al., 1984). This motif, the helix-turn-helix (HTH),
was first described in bacterial transcriptional repressors
(Pabo & Sauer, 1984). X-ray crystallography of homeo-
domain-DNA co-crystals has confirmed this structure and
shown that, as with the prokaryotic HTH, one of the helices
lies in the major groove of the DNA double helix, contacting
the bases, whilst the others are positioned perpendicular to
this, and predominantly contact the phosphate backbone
(Kissinger et al., 1990). In the POU domain, found in a
related group of proteins (including Pit-l, Oct, and Unc 86),
a homeobox and a 'POU-specific' domain are separated by a
short spacer (Herr et al., 1988). The POU-homeodomain,
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tional regulation may also be important in neoplasia. A
number of possible mechanisms might be envisaged (Figure
6): firstly, transcription factors regulating genes involved in
cell growth and division might be inappropriately expressed;
secondly, mutations in the protein coding sequence of such
factors might alter their ability to activate transcription or
might affect their interaction with other parts of the trans-
criptional machinery; thirdly, mutations in the DNA-binding
domain of a transcription factor or exchange of DNA-bind-
ing domains between unrelated factors could change the
target genes activated, resulting in stimulation of cell
division; and, finally, transcription factors which normally
mediate differentiation or which repress cell growth might be
deleted or inactivated.
Some oncogenes encode transcription factors
b
Figure 5 The zinc finger and the homeodomain. a, A suggested
structure for the zinc finger motif. A zinc ion (Zn) is complexed
by two cysteine (C) residues on descending and ascending
stretches ofP-sheet (shaded) and two histidines (H) in an a-helical
region (hatched). The finger is formed by the amino acids
between the distal cysteine and the proximal histidine. b, Interac-
tion of the engrailed homeodomain with DNA (Adapted from
Kissinger et al., 1990). Helix 3 lies in the major groove of the
DNA double helix with several amino acids contacting the bases,
whilst helices I and 2 span the groove.
unlike the pure homeobox which is sufficient for DNA bind-
ing on its own, requires an appropriately placed POU-specific
domain to bind its cognate sequence efficiently (Sturm &
Herr, 1988).
The regions of transcription factors involved in transcrip-
tional activation or repression are less well conserved,
although certain recurrent themes can be recognised. In par-
ticular, such domains may contain a preponderance of amino
acids with acidic side chains, or alternatively a single amino
acid, such as proline or glutamine may be especially abun-
dant. The relationship between the structure of these areas
and their ability to modulate the rate of initiation of trans-
cription by the RNA polymerase is as yet poorly understood,
but one would expect proteins with similar activation
domains to act in a similar way.
The structural elements described above are not the only
ones capable of forming dimers, of binding to DNA in a
sequence specific manner or of activating transcription. Other
families are emerging whose conserved domains do not fit
any of the above models, but with time, doubtless their
structure will also be resolved.
Neoplasia
With such a fundamental role in the control of cellular
function it is hardly surprising that aberrations in transcrip-
Oncogenes were first identified as the transforming genes of
highly oncogenic retroviruses (Martin, 1970). Later it was
discovered that viral oncogenes are modified forms of normal
cellular genes, so-called proto-oncogenes, the products of
which are involved in the control of cell growth and pro-
liferation. Inappropriate expression of these genes results in
transformation of cells in culture.
Many proto-oncogene products are growth factors, surface
membrane receptors and cytoplasmic or membrane bound
proteins normally involved in the receipt and transduction of
growth signals (for review see, Varmus & Bishop, 1986). A
number, including myc, myb,fos,jun and Erb-A, are found in
the nucleus, where it has been proposed that they provide the
final stage in the signalling pathway (Pawson, 1987). Recent
work has demonstrated thatjun, fos, myb, Erb-A and prob-
ably myc are involved in transcriptional regulation.
Thejun-fos story
The first example of an oncogenic transcription factor was
v-jun, the transforming gene of the chicken sarcoma virus
ASV17 (Maki et al., 1987). The amino acid sequence of the
product of this gene was compared to other known proteins
and part of it was found to be very similar to the DNA-
binding domain of the yeast transcription factor, GCN4
(Vogt et al., 1987). When the DNA-binding domain of
GCN4 was replaced with the homologous region ofv-jun, the
chimLeric protein continued to function as a transcription fac-
tor (Struhl, 1988), suggesting that the v-jun product would
also bind to DNA. Its function, however, remained un-
known.
AP-1 is a transcription factor (or family of factors) involv-
ed in mediating the transcriptional response to activation of
protein kinase C. It recognises variations on the DNA
sequence TGACT(C/A)A (A = adenosine, t = cytidine, G =
guanosine, T = thymidine) (Lee et al., 1987; Angel et al.,
1987), which is very similar to the cognate sequence of
GCN4 (ATGA(C/G)TCAT) (Hill et al., 1986). Monoclonal
antibodies raised against different regions of v-jun were
shown to precipitate AP-l, but not other transcription fac-
tors, from nuclear extracts (Box et al., 1988) and subse-
quently the peptide sequence of the 47 kD protein in purified
API preparations was shown to be identical to c-jun (Angel
et al., 1988). When compared to c-jun, v-jun shows two
amino acid changes in the DNA-binding domain and a dele-
tion towards its N-terminus, in the region responsible for
transcriptional activation (Vogt & Tjian, 1988). The deletion
removes part of the protein required for interaction with a
cell-type specific repressor factor, possibly freeing the viral
protein from normal control and thus rendering it oncogenic
(Baichwal & Tjian, 1990).
Following the discovery that thejun oncogene was a trans-
cription factor, evidence emerged linking it to another
oncogene, v-fos, the transforming gene of the Finkel-Biskis-
Jinkins murine sarcoma virus (FBJ-MuSV) (van Beveren et
al., 1983). Its cellular counterpart, c-fos, is a nuclear phos-
phoprotein expressed transiently in many cell types in res-
a656 P.M. COX & C.R. GODING
ponse to mitogenic and other stimuli (Curran et al., 1984).
Immune precipitation experiments demonstrated the presence
of c-fos in complexes binding to the AP-1 sequence (Distel et
al., 1987). A number of other proteins were co-precipitated as
a result of interaction with fos, the most abundant of which
was c-jun/AP-1 (Sassone-Corsi et al., 1988; Rauscher et al.,
1988).
Analysis of the protein structure offos and jun revealed
that each has a leucine zipper, which enables protein-protein
interactions necessary for DNA binding (Kouzarides & Ziff,
1989; Vinson et al., 1989). Fos is unable to form homodimers
and thus cannot bind to DNA on its own, whilst jun-jun
homodimers bind only weakly to the API recognition site. In
contrast, fos-jun heterodimers are stable, bind strongly to
CELL X
CELL Y
CELL Z
Figure 6 Transcription and transformation. Cell X. Gene I is not expressed due to mutation (*) of the activator domain of 'b',
whilst transcription of gene, 3, is activated as a result of(i), production of a chimaeric factor, due to a chromosomal translocation,
composed of the activator domain of 'h' linked to the DNA-binding domain of the normally silent factor 'g', combined with (ii)
loss of the repressor 'j'. Cell Y. Gene 2, normally active in cell Y, is not expressed, due to a mutation in the DNA-binding domain
of 'e', whilst another DNA-binding domain mutation in 'd' allows promiscuous activation of gene 3 via site G. Cell Z. Failure to
express factor 'a' inactivates gene 2, whilst inappropriate expression of 'f' and an activating mutation of 'g' lead to strong
transcription of gene 3.
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API sites and activate transcription (Smeal et al., 1989).
V-fos differs from c-fos in its C-terminal 49 amino acids as a
result of a deletion which alters the reading frame of the viral
gene (van Beveren et al., 1983). However, both v-fos and
c-fos proteins form specific DNA-binding heterodimers with
jun, which activate transcription from TPA-responsive
elements (Rauscher et al., 1988; Chiu et al., 1988) and both
will transform fibroblasts (Miller et al., 1984). Therefore, it
appears that it is loss of normal regulation of fos protein
expression and not the altered C-terminus, which is respon-
sible for a transforming ability of v-fos.
Subsequently, a number of other proteins which share the
bZip domain present in jun and fos have been identified
(Ryder et al., 1988; Ryder et al., 1989; Hirai et al., 1989;
Zerial et al., 1989; Cohen & Curran, 1988) and have been
shown to be capable of selectively forming heterodimers
(Smeal et al., 1989; Kouzarides & Ziff, 1989; Hai et al.,
1989). This gives rise to a considerable repertoire of protein
combinations able to bind to the same, or closely related,
DNA sequences under different conditions and enables subtle
and specific transcriptional regulation of many genes.
The myc oncogenes
One of the earliest viral transforming genes to be recognised
was that carried by the avian retrovirus MC29, v-myc. The
protein products of its cellular counterpart, c-myc, and the
related L- and N-myc genes, are expressed in the nucleus
(Abrams et al., 1982; Donner et al., 1982) and show a rapid
response to growth stimuli (Kelly et al., 1983). Inappropriate
expression of different members of the myc family, either
alone or in conjunction with chromosomal translocation or
gene amplification, has been demonstrated in a number of
human tumours (Erikson et al., 1983; Cole, 1986; Nau et al.,
1985; Schwab et al., 1983). In addition, like fos, myc can
complement ras oncogenes in transforming cells (Land et al.,
1983). However, the function of the myc proteins has remain-
ed a mystery, for although they could be shown to bind
non-specifically to DNA (Abrams et al., 1982), little more
was known. Recently, however, the myc proteins were shown
to possess the basic/helix-loop-helix (bHLH) motif. This
domain is also found in a number of known and putative
transcription factors involved in differentiation and tissue-
specific gene expression (Davis et al., 1990; Murre et al.,
1989a, b). To the C-terminal side of the bHLH domain, myc
also has a leucine zipper domain, similar to that present in
fos and jun, which has also been shown to be necessary for
the formation of myc multimers, but which also may enable
interaction with other proteins (Dang et al., 1989). These
data suggest strongly that myc functions, at least in part, as a
transcription factor and that it has the potential for inter-
action with a wide variety of other proteins.
c-myb
The oncogene v-myb, carried by two chicken retroviruses,
avian myeloblastosis virus and E26, is a truncated version of
the cellular proto-oncogene c-myb (Gonda & Bishop, 1983;
Klempnauer et al., 1983) which encodes a nuclear protein of
MW 75-80 kD (Klempnauer et al., 1983, 1984, 1986)
expressed in immature, but not in differentiated haemato-
poietic cells (Duprey & Boettiger, 1985). When chicken bone
marrow cells are transformed with v-myb their differentiation
is blocked and they have the phenotype of myeloid precur-
sors (Gazzolo et al., 1979), whilst overexpression of c-myb
prevents the induction of differentiation of cultured eryth-
roleukaemia cells (McMahon et al., 1988). Both v- and c-myb
bind specifically to the sequence PyAACG/TG (Py
=pyrimi- dine) and activate transcription from reporter genes (i.e. foreign genes with assayable products) linked in cis to this
motif (Howe et al., 1990; Weston & Bishop, 1989; Sakura et
al., 1989). A cellular gene, miml, encoding a promyelocyte specific secretory protein, which is activated by myb, has been
identified (Ness et al., 1989). Very recently, it has been shown
that phosphorylation of certain serine residues in c-myb, by
casein kinase II, prevents it from binding to DNA. The
region of c-myb containing these residues is deleted from
v-myb and activated c-myb genes (Luscher et al., 1990).
Transformation is probably the result of expression of a myb
protein which cannot be prevented from binding to DNA
and which thus inappropriately activates transcription from
genes responsible for cell growth.
Other nuclear oncogenes
At least five other known viral oncogenes encode proteins
which are, or are extremely likely to be, deregulated trans-
cription factors. The best characterised of these is v-ErbA,
one of the transforming genes of the avian erythroblastosis
virus, which encodes a truncated thyroid hormone receptor
(Sap et al., 1986; Weinberger et al., 1986), a relative of the
steroid hormone receptors (see above) (Evans, 1988; Thomp-
son & Evans, 1989). As a result of deletion of part of the
C-terminus of the normal receptor, the viral ErbA protein is
unable to bind thyroid hormone. It does, however, bind
correctly to thyroid hormone-responsive DNA elements,
functioning as a constitutive repressor of thyroid hormone
responsive genes and competitive antagonist of the normal
thyroid hormone receptor/ligand complex (Damm et al.,
1989), suggesting that it may transform erythroblasts by
blocking thyroid hormone-mediated differentiation.
v-ets is a second oncogene present in the genome of avian
leukosis virus, E26, which also bears v-myb and is necessary
for it to induce erythroblastosis (Leprince et al., 1983; Nunn
et al., 1983; Nunn & Hunter, 1989). The product of the
chicken proto-oncogene, c-ets-l, from which it is derived, is a
member of a family of nuclear phosphoproteins of short
half-life, expressed predominantly by proliferating cells (Fuji-
wara et al., 1988a, b; Pognonec et al., 1989). Ets and related
proteins are also present in insects and other vertebrates
(Pribyl et al., 1988; Reddy et al., 1987; Rao et al., 1989) and
all share a highly conserved region of basic amino acids at
the C-terminus (Watson et al., 1988). c-ets-l binds specifically
to a cis-acting element in the long terminal repeat (LTR) of
the Moloney murine sarcoma virus (Gunther et al., 1990)
and to a closely related sequence, PEA3, in the polyoma
virus enhancer. It activates transqiption from these sequen-
ces and, in the polyoma enhancer, functions cooperatively
with members of thefos-jun family which bind to an adjacent
API site (Wasylyk et al., 1990). In addition, juxtaposed API
and PEA3 sites are found in the promoter of a number of
oncogene-responsive genes (Wasylyk et al., 1989).
The avian retrovirus ReVT, which causes rapidly progres-
sive lymphoid tumours in birds, carries the v-rel oncogene
(Stephens et al., 1983). Its product is found in the nucleus of
some cells and in the cytoplasm ofothers (Gilmore & Temin,
1988). The proto-oncogene c-rel has recently been shown to
be related to, and capable ofparticipating in heterotetrameric
complexes with one subunit of NFjcB, a multifunctional
transcription factor, and dorsal, a Drosophila protein involv-
ed in dorsal/ventral axis determination (Kieran et al., 1990;
Ghosh et al., 1990). NFicB is produced as a large non-DNA
binding precursor and its activity may be regulated partly
through the rate of cleavage of this molecule to a smaller
form. However sequestration in the cytoplasm by the related
protein IKB, which cannot bind to DNA, is probably more
important (Bauerle & Baltimore, 1988). It appears that,
unlike c-rel, v-relcannot activate transcription, but it retains
the ability to interact with other related proteins. Thus it may
interfere with the normal equilibrium between active and
inactive complexes and lead to aberrant transcriptional
regulation.
The nuclear oncogenes v-ski and v-maf are less well char-
acterised than those described above. V-ski was isolated from
an avian leukosis virus in culture and the protein it encodes
has several features which suggest it may be a transcription
factor (Stavnezer et al., 1989). The function of the c-ski
proto-oncogene from which it is derived is unknown, how-
ever transformation of quail embryo cells with v-ski causes
them to undergo myogenic differentiation suggesting a rela-658 P.M. COX & C.R. GODING
tionship to the MyoD family of myogenic proteins (Davis et
al., 1990; Colmenares & Stavnezer, 1989). V-maf, which
causes naturally occurring fibrosarcomas in fowl, shows
regions of structural similarity to the fos and jun oncogenes
having both a leucine zipper motif (Nishizawa et al., 1989)
and an adjacent domain of basic amino acids which fits the
consensus sequence of the bZip proteins (Vinson et al., 1989).
In addition it has stretches of uninterrupted glycine and
histidine residues, a single polyglycine sequence being a
feature of the leucine zipper transcription factor, C/EBP
(Landschulz et al., 1988b).
Abnormalities oftranscription factors in human tumours
Whilst the identification and characterisation of oncogenic
transcription factors has told us much about the mechanisms
of transcriptional control and deregulation, to date only the
expression of myc proto-oncogenes, whose transcriptional
role is still not finally proven, has been shown to be abnor-
mal in human tumours. However, some recent work has
demonstrated more clearly the direct role of other transcrip-
tion factors in human neoplasia (Table I).
Pre-B ALL and helix-loop-helix proteins
The tumour cells of 30% of patients with childhood pre
B-Acute Lymphoblastic Leukaemia (pre B-ALL) carry the
translocation t(1:19) (q23:pl3.3) (Williams et al., 1984). Two
groups investigating the translocation breakpoint have shown
that a chimwric gene is produced, from which a potentially
functional transcription factor is synthesised (Nourse et al.,
1990; Kamps et al., 1990). The N-terminal part of the novel
protein is contributed by the E2a gene from chromosome 19,
encoding the myc-related proteins E12 and E47, which nor-
mally stimulate constitutive transcription from the kappa
immunoglobulin promoter in B-cells (Murre et al., 1989b;
Moss et al., 1988). The part of the protein retained in the
chimwric factor is the potent transcriptional activator domain.
The C-terminus, encoded by part of a gene on chromosome
1, normally inactive in pre-B lymphocytes, is the homeo-
domain of a newly identified factor of unknown function,
designated prl. Many of the proteins sharing this structural
feature are involved in developmental and tissue-specific
regulation of gene expression (Gehring, 1987; Ingraham et
al., 1988; Scheidereit et al., 1988; Johnson & Hirsh, 1990).
Thus, the result of the pre B-ALL translocation is a protein
which may be capable of strongly activating a gene or group
of genes involved in the control of normal differentiation and
not normally expressed at this stage oflymphocyte ontogeny.
Two additional bHLH proteins, relatives of E12/E47, have
been implicated in different forms of acute leukaemia. One,
SCL, was identified as the protein encoded by the gene on
chromosome 1 involved in the breakpoint of the transloca-
tion, t(l:14) (p33;ql1.2) in a primitive acute leukaemia cap-
able of both myeloid and lymphoid differentiation. The nor-
mal SCL gene is expressed by haematopoietic stem cells and
myeloid and T lymphocyte precursors (Begley et al., 1989)
whilst an aberrant mRNA, including at its 3' end part of the
T-cell receptor (TCR) 6 chain gene, is produced by tumour
cells. The same gene is also involved in the translocation
t(l:14) (p32;ql 1) in a small group ofT-cell acute lymphoblas-
tic leukaemias (T-ALL) (Chen et al., 1990). In these malig-
nant cells the SCL gene is fused to the 5' part of the TCR 6
gene and thus it may be expressed under the control of an
inappropriate promoter. The second protein, designated Lyl-
1, is closely related to SCL and is expressed in another subset
of T-ALLs, in a truncated form, as the result of a t(7:19)
translocation which juxtaposes its gene to that of the TCR P
chain (Mellentin et al., 1989). Further study of these proteins
should give valuable insight into the role of transcription in
normal haematopoietic development and in neoplasia.
Wilms' tumour and the zincfingerproteins
Gross cytogenetic deletions and rearrangements affecting
chromosome 11 (band p13) are common finding in hereditary
and some sporadic Wilm's tumours. The gene inactivated by
these changes encodes a protein (the WT protein) with four
'zinc fingers' near to its C-terminus suggesting that it is a
transcription factor (Call et al., 1990; Gessler et al., 1990). Its
N-terminus is rich in both proline and glutamine residues,
amino acids occurring frequently in the activation domains
of some other transcription factors (Mermod et al., 1989;
Tanaka & Herr, 1990). The gene is strongly expressed in the
embryonic kidney and its product appears to be required for
the switch from mesodermal to epithelial differentiation
which occurs in the developing urogenital sysem (Pritchard-
Jones et al., 1990). The mechanism by which homologous
deletion or rearrangement of the WT gene leads to the
uncontrolled proliferation of nephroblasts is unknown, but
one might speculate that the normal WT protein stimulates
their differentiation into nephrons and its inactivation allows
continued growth and division. This is supported by the
inability of nephroblastoma cells transfected with a normal
chromosome 11, to form tumours, but more definitive work
is awaited (Weissman et -a., 1987).
In acute promyelocytic leukaemia (APL; FABM3), tumour
cells carry the translocation t(15:17) (q22; qll.2-ql2) in
approaching 100% of cases (Sheer et al., 1984). The chromo-
some 17 breakpoint has been characterised in a number of
cases and shown to fall in the first intron of the retinoic acid
receptor a (RARA) gene (Borrow et al., 1990). The product
of this gene is related to the steroid hormone receptors, and
as a result of the translocation, the first exon, which encodes
the transcription activation domain, is separated from the
DNA-binding and ligand-binding domains, which become
part of the derivative chromosome 15. The gene to which
they are attached awaits characterisation, but as with pre-B
ALL the resultant fusion protein is likely to be of great
importance in understanding the behaviour of the tumour
cells and probably explains the response of APL to retinoic
acid.
Other zinc finger proteins have also been implicated in
neoplasia. The gene GLI, on chromosome 12, is amplified in
a proportion of human malignant gliomas (Kinzler et al.,
1987). Evidence suggests that the GLI protein may be
involved in normal development as it is most closely related
to the 'Kruppel' zinc finger proteins (Kinzler et al., 1988)
involved in Drosophila segmentation (Schuh et al., 1986;
Chowdhury et al., 1987) and is produced by embryonal
carcinoma cells but not by adult tissues.
The translocation, t(I1:14) (p15;ql1), present in a group of
T-ALL activates the gene, ttg, (McGuire et al., 1989; Boehm
et al., 1988), which encodes a zinc finger protein normally
expressed in the developing nervous system and in certain
regions of the mature brain (Greenberg et al., 1990). It is
likely that that proteins described above are not the only
developmentally regulated transcription factors with a role in
transformation.
Future prospects
In addition to yielding a greater understanding of the malig-
nant process, the study of transcription may also provide
advances in the diagnosis, assessment of prognosis and treat-
ment of cancer. Whilst the inappropriate expression or
repression of various genes may underlie the behaviour and
histological appearance of a malignant tumour, in reaching a
diagnosis the pathologist relies, to a great extent, upon the
persistence of some features of differentiation in the tumour
cells. For example, the identification of cytokeratins in
epithelial tumours; of melanin and neuroendocrine markers
in melanomas; of desmin, myoglobin and the cross striations
produced by the contractile machinery of skeletal muscle in
rhabdomyosarcomas; and of leucocyte common antigen in
lymphomas frequently aids assessment. Unfortunately, theseTRANSCRIPTION AND CANCER 659
Table I Some abnormalities oftranscription factors in human tumours
Tumour % Genes Mechanism Result
Pre-B-ALL 30 E2a t(l:l9) Chimaeric protein"2
prl
Stem cell - SCL/tal t(l:14) Abnormal mRNA3
Leukaemia TCR6
T-ALL 2-20 SCL/tal t(l:14) Inappropriate
TCR6 expression4
T-ALL < 10 lyl-l t(7:19) Truncated mRNA5
TCRP
T-ALL 10 ttg t(I1:14) Inappropriate
TCR6 expression6
T-ALL < 10 c-myc t(8:14) Inappropriate
TCRx/6 expression7
Wilms' Tumour WT deletion/mutation Inactivation89
APL clOO RARA t(15:17) Chimaeric protein'
Malignant glioma 4 gli Amplification Overexpression""2
Burkitt's lymphoma 75 c-myc t(8:14) Inappropriate
16 IgH/jc/k t(8:22) expression'3"4
9 t(2:8)
Various - c-myc Amplification Overexpression
Refs: 'Nourse et al., 1990; 2Kamps et al., 1990; 3Begley et al., 1989; 4Chen et al., 1990;
5Mellentinetal., 1989; 6McGuireetal., 1989; 7Shimaetal., 1986; 8Calletal., 1990;9Gessler
etal., 1990; '0Borrowetal., 1990; "Kinzleret al., 1987; '2Wongetal., 1987; 3Eriksonetal.,
1983; '4Nishikura et al., 1983.
markers are produced in different amounts by individual
tumours of the same type and in a proportion no evidence of
differentiation can be identified, making classification and
therefore rational treatment difficult.
The identification of tissue-specific transcription factors in
cancer cells could offer a considerable advance in tumour
diagnosis. As described above, it is likely that transcription
factors are responsible for determining the line of different-
iation undertaken by a cell and such factors must be express-
ed prior to the genes which they regulate. Already a number
of proteins controlling muscle-specific gene expression, which
cause differentiation of fibroblasts into skeletal muscle have
been cloned (Davis et al., 1990; Miner & Wold, 1990; Braun
et al., 1989; Braun et al., 1990; Wright et al., 1989; Rhodes &
Konieckny, 1989), whilst factors binding to HMW keratin
promoters have been identified in keratinocytes (Lersch et al.,
1989; Jiang et al., 1990). In the future the demonstration of
tissue-specific transcription factors within otherwise undiffer-
entiated tumour cells may enable a correct diagnosis to be
reached and thus appropriate chemotherapy to be given.
With regard to prognosis and treatment, assessment and
manipulation oftranscription factors is already commonplace
in many centres; the oestrogen and progesterone receptor
status of breast carcinomas is a routinely applied and valu-
able, prognostc indicator (DeSombre et al., 1979; Maynard et
al., 1978) and administration of tamoxifen, a competitive
oestrogen antagonist, is a standard treatment. When tamox-
ifen binds to the oestrogen receptor, dimerisation and DNA
binding occur normally, but transcriptional activation is
inhibited (Kumar & Chambon, 1988). Thus oestrogen-medi-
ated stimulation of growth-related genes is prevented. A
similar situation is likely to result from the administration of
anti-androgens, such as cyprotersone acetate, to patients with
prostatic carcinoma. The treatment of lymphoma with corti-
costeroids may act via the glucocorticoid receptor either to
suppress transcription from genes involved in cell division or
to stimulate differentiation (Beato, 1989; Thompson, 1989).
In the future, as a greater understanding of the transcrip-
tional machinery is gained, it is likely firstly, that other
transcription factors will be identified whose production by a
tumour will correlate with a better or a worse prognosis and
secondly, that drugs will be developed which can interact
with the transcriptional machinery to repress cell growth and
division or stimulate differentiation of tumour cells. Whilst
this is currently only speculation, transcription-related
research should soon yield major dividends for cancer
patients.
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